UroGen Pharma/$URGN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
$URGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
234
ISIN
IL0011407140
Website
UroGen Pharma Metrics
BasicAdvanced
$626M
-
-$3.04
0.67
-
Price and volume
Market cap
$626M
Beta
0.67
52-week high
$18.15
52-week low
$3.42
Average daily volume
4.8M
Financial strength
Current ratio
5.647
Quick ratio
5.132
Long term debt to equity
-268.95
Total debt to equity
-271.994
Interest coverage (TTM)
-7.56%
Profitability
EBITDA (TTM)
-106.578
Gross margin (TTM)
89.68%
Net profit margin (TTM)
-150.68%
Operating margin (TTM)
-116.31%
Effective tax rate (TTM)
-2.34%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-29.80%
Return on equity (TTM)
319.73%
Valuation
Price to revenue (TTM)
6.721
Price to book
-13.48
Price to tangible book (TTM)
-13.48
Price to free cash flow (TTM)
-5.749
Free cash flow yield (TTM)
-17.39%
Free cash flow per share (TTM)
-236.20%
Growth
Revenue change (TTM)
8.98%
Earnings per share change (TTM)
-5.79%
3-year revenue growth (CAGR)
19.29%
3-year earnings per share growth (CAGR)
-15.50%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
Bulls say / Bears say
Scotiabank initiated coverage of UroGen Pharma with a 'Sector Outperform' rating and a $23.00 price target, indicating strong confidence in the company's growth prospects. (nasdaq.com)
UroGen Pharma reported Q3 2024 revenues of $25.2 million, surpassing consensus estimates and reflecting a 20% year-over-year increase, demonstrating robust financial performance. (nasdaq.com)
The company's lead candidate, UGN-102, shows promise in treating low-grade intermediate-risk non-muscle invasive bladder cancer, with significant clinical trial success and a PDUFA date set for June 13, 2025. (seekingalpha.com)
UroGen Pharma reported a Q4 2024 loss of $0.80 per share, missing consensus estimates and indicating ongoing financial challenges. (nasdaq.com)
Goldman Sachs maintains a 'neutral' rating on UroGen stock, suggesting limited upside potential in the near term. (investing.com)
Insider selling activity, including the sale of 4,551 shares by insider Mark Schoenberg, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
UroGen Pharma News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
GlobeNewsWire·3 days ago
URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information
GlobeNewsWire·4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $626M as of July 04, 2025.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of July 04, 2025.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.